The manufacturers of pramipexole predict that its clearance will be reduced by
amantadine.
The
clinical significance of this is uncertain, and there appear to be no reports of any adverse interactions. The manufacturers suggest a reduction of the pramipexole dose should be considered in patients taking
amantadine.